Xeltis is a clinical-stage medical device company developing the first heart valves and blood vessels enabling the body’s natural restoration of heart valve function through a therapeutic approach called Endogenous Tissue Restoration (ETR). The company’s cardiovascular implants are made of bioabsorbable polymers based on Nobel Prize- awarded science. Xeltis closed a €45 million Series C financing round in 2017 to advance its aortic and pulmonary valve programs.